Table 3.
Changes in lab parameters and KCCQ
| Vitamin D | 95% CI | Placebo | 95% CI | p-value | Corrected model p-value | |
|---|---|---|---|---|---|---|
| BNP | 30 ± 950 | −10, 70 | 400 ± 1900 | 210–600 | 0.002* | 0.003* |
| PTH | −20 ± 20 | −28, −11 | 7 ± 53 | 16, 30 | <0.002* | 0.07 |
| hsCRP | −1 ± 5 | −3, 1 | 1 ± 6 | −2, 4 | 0.18 | 0.21 |
| 25-(OH)D | 51 ± 32 | 39,62 | 1 ± 6 | −2, 3 | <0.001* | Na |
| Physical Score | 9 ± 14 | 3,15 | −5 ± 20 | −4, 14 | 0.02* | 0.07 |
| Symptom Frequency | 10 ± 28 | −2, 28 | −6 ± 17 | −2, 13 | 0.03* | 0.06 |
| Symptom Burden | 12 ± 20 | 3, 20 | −7 ± 15 | −14, 0 | 0.002* | 0.05* |
| Total Symptom | 11 ± 22 | 1, 22 | −6 ± 17 | −13, 1 | 0.013* | 0.03* |
| Stability Score | 3 ± 35 | −13, 18 | 1 ± 14 | −5,7 | 0.88 | 0.84 |
| QOL Score | 11 ± 21 | 3, 21 | −2 ± 20 | −11, 7 | 0.05* | 0.11 |
| Social Score | 10 ± 24 | 0, 24 | −4 ± 27 | −16, 8 | 0.14 | 0.27 |
| Overall Summary Score | 10 ± 15 | 4,17 | −6 ± 15 | −13, 1 | <0.02* | 0.01* |
| Clinical Summary Score | 8 ± 14 | 2, 14 | −8 ± 18 | −16, 0 | 0.02* | 0.01* |
Data are expressed as mean ± SD, 95% CI
Abbreviations: Kansas City Cardiomyopathy Questionnaire (KCCQ), Standard Deviation (SD), Confidence Interval (CI), B-type Natriuretic Peptide (BNP), Parathyroid Hormone (PTH), high sensitivity c-reactive protein (hsCRP), 25 hydroxyvitamin D (25-(OH)D), Quality of Life Score (QOL)
*Indicates significant difference between groups